Weilheim In Oberbayern

Researchers are evaluating the real-world effectiveness, safety, and tolerability of ribociclib combined with an aromatase inhibitor, with or without luteinizing hormone-releasing hormone (LHRH) therapy, for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. The study also compares data from patients treated with abemaciclib plus endocrine therapy with or without LHRH, and those receiving endocrine monotherapy with or without LHRH. This observational study aims to understand treatment decisions and clinical use of ribociclib after its approval, collecting socio-economic data, quality of life, and patient compliance information. Participants receive treatment based on their physician's clinical judgment without study-assigned interventions. The treatments observed include ribociclib with an aromatase inhibitor LHRH, abemaciclib with endocrine therapy LHRH, or endocrine monotherapy LHRH. The study is conducted in various breast cancer centers and gynecological practices in Germany and Austria to represent local healthcare settings. Participants undergo assessments to monitor treatment effectiveness, safety, quality of life, and adherence to therapy over time. Data collected include clinical outcomes, adverse events, socio-economic status, and patient-reported compliance. The primary outcome measured is invasive disease-free survival over 36 months. This information will help inform clinical decision-making and improve outcomes for patients with early breast cancer in routine practice.

Researchers are evaluating the effectiveness and safety of a subcutaneous cladribine treatment for patients with hairy cell leukemia who need therapy. This study focuses on patients who are either untreated or have only been pretreated with alpha-interferon. It aims to assess remission rates four months after treatment and whether a second cycle benefits those with a non-optimal response, defined by residual disease or partial remission. Participants receive cladribine 0.14 mg/kg as a subcutaneous bolus injection once daily for five consecutive days. If the response after the first cycle is not optimal, patients may receive a second cycle of the drug to improve their remission status. This treatment approach is being studied in a Phase 2/3 clinical trial setting. During the study, remission status is evaluated four months after the first treatment cycle. Patients undergo assessments to detect residual disease in bone marrow and peripheral blood. Researchers monitor the rate of complete remissions and any treatment-related toxicities. The overall health, laboratory tests, and disease markers are regularly checked throughout the study period to ensure safety and to measure the treatment's impact.